Related Experiment Video
Updated: Oct 20, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies
Narendra Wajapeyee1,2, Romi Gupta1,2
1Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama. nwajapey@uab.edu romigup@uab.edu.
Abstract:
Cancer is a complex disease and cancer cells typically harbor multiple genetic and epigenetic alterations. Large-scale sequencing of patient-derived cancer samples has identified several druggable driver oncogenes. Many of these oncogenes can be pharmacologically targeted to provide effective therapies for breast cancer, leukemia, lung cancer, melanoma, lymphoma, and other cancer types. Initial responses to these agents can be robust in many cancer types and some patients with cancer experience sustained tumor inhibition. However, resistance to these targeted therapeutics frequently emerges, either from intrinsic or acquired mechanisms, posing a major clinical hurdle for effective treatment. Several resistance mechanisms, both cell autonomous and cell nonautonomous, have been identified in different cancer types. Here we describe how alterations of the transcriptome, transcription factors, DNA, and chromatin regulatory proteins confer resistance to targeted therapeutic agents. We also elaborate on how these studies have identified underlying epigenetic factors that drive drug resistance and oncogenic pathways, with direct implications for the prevention and treatment of drug-resistant cancer.
Insights
Targeted cancer therapies show initial promise but drug resistance frequently emerges. Understanding epigenetic factors driving resistance is crucial for developing effective treatments for drug-resistant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Cancer involves complex genetic and epigenetic alterations.
- Targeted therapies based on driver oncogenes offer effective treatments for various cancers.
- Therapeutic resistance is a significant clinical challenge.
Purpose of the Study:
- To review mechanisms of resistance to targeted cancer therapeutics.
- To highlight the role of epigenetic factors in driving drug resistance.
- To discuss implications for preventing and treating drug-resistant cancers.
Main Methods:
- Analysis of large-scale sequencing data from patient-derived cancer samples.
- Review of studies identifying molecular alterations conferring resistance.
- Elaboration on epigenetic factors and oncogenic pathways.
Main Results:
- Targeted therapies can lead to robust initial responses but resistance often develops.
- Mechanisms of resistance include alterations in transcriptome, transcription factors, DNA, and chromatin regulators.
- Epigenetic alterations are key drivers of drug resistance and oncogenic pathways.
Conclusions:
- Understanding resistance mechanisms is vital for overcoming therapeutic limitations.
- Epigenetic modifications play a critical role in acquired drug resistance.
- This knowledge has direct implications for developing novel strategies against drug-resistant cancers.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Epigenetic Regulation
X-chromosome...
Mitogens and the Cell Cycle
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...